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Abstract
Background: Cancer is a disease that gets serious attention in the medical world. This is due to the ever increasing
number of patients and there has been no effective way to treat. Cancer cells have telomerase activity is relatively high
compared to normal cells, so the cancer cells have the ability to continue to proliferate. Cancer cells undergo
uncontrolled mitosis and have high telomerase activity compared to cells normal. Telomerase is an enzyme responsible
for telomere length, a segment of DNA that is the tip of chromosomes in eukaryotic cells. Telomeres are associated with
the process of ageing and carcinogenesis. The purpose of this study was to determine the expression of telomerase in
some cells such as breast cancer, cervical cancer, and lung cancer. Methods: The research method is experimental
studies in several cancer cell cultures in the form of cell line. Cancer cells used were: HeLa (cervical cancer), MCF7
and T47D (breast cancer), WiDr (lung cancer), and Raji (lymphoma) with culture medium RPMI, DMEM, and M199.
Vero cells is used (fibroblast cells) as a control (normal cells). Expression of telomerase enzyme was measured by the
Immunohystochemistry (IHC) method. Results: The results showed that the cancer cells have activity/higher
telomerase expression were highly significant (p < 0.01) compared to normal cells (Vero cells). Similarly, the
expression of telomerase in HeLa versus WiDr, WiDr versus T47D, T47D versus Raji, and Raji versus MCF7 also
showed highly significant differences (p < 0.01). Telomerase expression between cancer cells that showed significant
difference (HeLa cells versus Raji cells; HeLa cells versus MCF7 cell; T47D cells versus MCF7 cells) (p < 0.05). No
significant difference was found in the group of HeLa cells versus T47D, WiDr versus Raji cells, and WiDr versus
MCF7. Conclusions: It was concluded, that the cancer cells have telomerase expression of specific and different from
each other, depending on the type of cell. T47D breast cancer cells have telomerase expression of the highest, followed
by cervical cancer cells (HeLa). Lung cancer cells (WiDr) with cell lymphoma (Raji) has almost the same expression
and both have lower expression.
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occurrence of cancer. Telomeres consist of highly
specific nucleotide sequence, the human sequence is
TTAGGG is repeated hundreds or even thousands of
times, so the formula is the nucleotide structure of
telomeres (TTAGGG) n. T, A, and G show the nucleotide
(DNA-forming compound collection) which contains
thymin, adenine, and guanine bases. In humans there are
2.000 repetitions on the base unit. In one organism in
different cell types, any number of repetitions of
different nucleotides.1,4 The length of telomeres play an
important role in maintaining genome stability and
regulate replication and cell death. In length or short
telomere is maintained by the enzyme telomerase,
which serves to lengthen telomeres and DNA damage
repair. The exact shape of this enzyme may different
from one species to another species, but each version
has a specific template RNA subunit to form a new
telomere.5,6 Telomerase activity in normal cells is mainly

Introduction
Cancer is a process that occurs gradually include initiation
(irreversible genetic changes) and promotion (population
of cells which extends initiation) and eventually malignancy.
It is known that the enzyme telomerase plays a role in
every cell replication that is able to maintain long
telomeres to offspring, so that when the cancer cells do
not have sufficient telomerase enzyme, then the growth
of cancer cells is stalled by itself.1,2 Of the several types
of cancer, cervical cancer remains the most common
cancer among women. It is the second major cause of
women’s death in Asia as well as in Indonesia.3
On the other side are known, genes contained in the
DNA molecule of a chromosome in the cell nucleus.
Segments of DNA on the ends of chromosomes known
as telomeres and is one of the factors related to the
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found in the reproductive cells because these cells have
unlimited proliferative power. Telomerase consists of two
functional components, namely the telomerase reverse
transcriptase (TERT, hTERT in humans) and telomerase
RNA template.7,8 Telomerase activity is mainly regulated
by hTERT gene that plays an important role in the growth
and development of tumours through the maintenance
of telomere length.8
The presence of the enzyme telomerase in a variety of
cancer cells each may give different expressions depending
on the type or location of the cancer cell and telomerase
is not found on normal cells. It can be used as the basis of
treatment of cancer cells if there are materials/substances
that can inhibit the activity of the enzyme telomerase.
Cancer cells have a high mitotic activity because cancer
cells undergo uncontrolled mitosis and have higher
telomerase activity compared to normal cells. There are
no reports or data more thoroughly on the enzyme
telomerase expression in several different types of
cancer cells. The purpose of this study was to determine
the expression of telomerase in several types of cancer
cells such as breast cancer, cervical cancer, and lung
cancer by in vitro.

Methods
In this research, the enzyme telomerase expression was
measured in cultured cancer cells (cell line) from breast
cancer, cervical cancer, lung cancer, and lymphoma.
The study consisted of six groups consisting of one
group of normal cells (Vero) as control and five other
groups are cancer cells (T47D, HeLa, WiDr, Raji, and
MCF7). Telomerase expression was measured by using
a technique Immunohystochemistry (IHC) and calculated
the percentage of cells which showed positive
expression.
Materials. Materials used in this study were breast
cancer cell line (T47D and MCF7), cervical cancer cell
line (HeLa), lung cancer cell line (WiDr), and
lymphoma cancer cell line (Raji). Also used a normal cell
line (Vero) as a comparison. Whole cell line was
obtained from the collection of the Laboratory of
Parasitology, Faculty of Medicine, Universitas Gadjah
Mada, Yogyakarta. The medium used is the medium
Roswell Park Memorial Institute (RPMI) 1640 (Sigma)
for cell Raji, T47D, HeLa, and WiDr; media Dulbecco's
Minimum Essential Medium (DMEM) (Gibco) for cells
MCF7 and medium M-199 (Sigma) for Vero cells. The
materials for IHC are Fetal Bovine Serum (FBS) (Gibco
BRL), Phosphate Buffer Saline (PBS), Sterptomisin
penicillin (Merck), telomerase antibody (Sigma) (Dako
Corporation), HEPES, SDS (Sodium Dodecyl Sulphate)
(Dako Corporation). The tools used in the study include
CO2 incubator (Inc 2 Memmert), autoclave (Cryolab 35),
laminair cabinet irflow (LAF) (Lab Konko), microscope
(Olympus), and tissue culture flasks (Nunclone).
Makara J. Health Res.
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Preparation of Culture Media and Growing of Cells.
Preparation of culture medium RPMI (Rosewell Park
Memorial Institute) is to dissolve the powder to one liter
of RPMI 1640 into akubides approximately 800 mL,
plus 2 g of sodium bicarbonate and HEPES 2 g, was
added to one liter of distilled water. The solution was
stirred with a magnetic stirrer about 10 minutes until
homogeneous, then neutralised with 1 N HCl to pH 7.2
to 7.4. Media of cells growing made by mixing FBS as
much as 19 mL, 2 mL Streptomycin penicillin,
Fungizone 0.5 mL, then diluted using RPMI 1640
culture medium to 100 mL. Furthermore, the solution
was filtered with a filter polyethene sulfone in aseptic
sterile 0.2 µm. Stored in the refrigerator by using a
sealed bottle.
Telomerase expression examination by Immunohystochemistry (IHC). Cell culture T47D, MCF7, HeLa, WiDr,
Raji and Vero with density 104 orwell already attached
to the coverslip performed immunohistochemical staining
(IHC) in the laboratory of Parasitology, Faculty of Medicine,
Universitas Gadjah Mada, Yogyakarta. Measurement
procedure telomerase expression with IHC method, as
follows: the cell culture coverslip that had been treated
were incubated at 5% CO2 incubator, temperature of
37 °C for 24 hours, taken and placed on a glass object
(poly-l-lysine slides), fixation with acetone or methanol
for 10 minutes at -20 °C. Then washed with PBS 3 x 5
min, then dropped 0.3% H2O2 for 20 minutes. After that
spilled with normal mouse serum (1:50) for 15 minutes,
the liquid discharged (without washing), then sprinkled
with primary antibody (telomerase) for 60 minutes. Wash
in PBS 3 times each for 5 minutes, then incubated in
secondary antibody biotin (biotinylated secondary antibody)
for 5-10 minutes, washed with PBS 3 times each for 5
minutes. Incubation in streptavidin-peroxidase enzyme
for 5-10 minutes, washed with PBS 3 times each for 5
minutes. Tetrahidrochloride deamino-benzidine incubation
in chromogen (DAB) for 5-10 minutes with chromogen
substrate ratio of 1:20, washed with distilled water.
Preparations immersed in hematoxylin for 3-5 minutes to
counterstain, washed with distilled water and dehydrated
performed using 95% ethanol, then with xylene each for
10 minutes. Further preparations spilled mounting media
(Canada balsam) and covered with a glass cover. Telomerase expression was observed using a light microscope.
Cells that express telomerase will give a brown color,
whereas cells that did not express the will give a purplish
blue color.

Results
Calculation of telomerase expression by IHC method is
done by counting the number of cells that showed positive
expression (brown nucleus and cytoplasm) of 100 cells
were examined. Calculations performed with 3 samples.
The results are expressed in percent. Percentage of
positive expression values are presented in Table 1.
April 2016 | Vol. 20 | No. 1
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The percentage of positive telomerase expression in
cancer cells showed high expression. ANOVA test results
showed the highly significant difference (p < 0.01)
between groups of cancer cells with normal cells or the
control group (Vero cells), with a value of F = 178.489
(Table 2).

Discussion
Telomerase is an ribonucleoprotein enzyme that maintains
protective structure at the ends of eucaryotic chromosomes,
called telomeres. Telomerase is a structure that is
responsible for the maintenance of telomeres, a replication
of nucleotides (TTAGGG) n. In most human somatic
cells, for example fibroblasts, suppressed the expression
of telomerase and telomeres shorten progressively at
each cell division. In contrast, most of the tumor cells or
human cancer cells expressing telomerase, resulting in
telomere length is stable. These observations suggest that
telomere maintenance is essential for the proliferation of
tumor cells or cancer.9,10 Telomerase activity determine
cell proliferation, both cancer cells and normal cells
under conditions in vitro and in vivo.11,12

The expression of telomerase in cancer cells in this study,
including breast cancer cells, cervical cancer, lung cancer,
and lymphoma showed higher expression than normal
fibroblast cells (Vero). Besides the magnitude of the
expression of telomerase in cancer cells, respectively,
differ from each other. The results of the multiple
comparison test LSD (Least Significant Difference)
between each group is presented in Table 3. Telomerase
expression in all groups of cancer cells (HeLa, WiDr,
T47D, MCF7, and Raji) results showed highly significant
difference (p < 0.01) than the control group (Vero). In
addition it is also showed highly significant difference
(p < 0.01) among the group of cancer cells as between
HeLa versus WiDr, WiDr versus T47D, Rajiv versus
T47D, and MCF7 versus Raji. Telomerase expression
was significant difference (p < 0.05) was found between
HeLa versus Raji, HeLa versus MCF7, T47D versus
MCF7, while between HeLa versus T47D, WDR versus
Raji, and WiDr versus MCF7 showed no significant
difference (p > 0.05).

Although telomerase activity in cancer cells increased
their activity, but De Lange reported that cancer cells
telomeres are shorter than the surrounding normal tissue.
The researchers speculate that telomerase becomes activated
after cells lose their ability to proliferate. Telomerase
activity in the cancer cells will increase after a certain
phase is when the cell loses some substance telomeric.
Finally, the enzyme telomerase is activated to stabilize
telomere, the cancer cells will be immortal cell, and there
was a continuous cell proliferation.1 Telomerase plays a

Table 1. The Average Value of the Percentage of Positive Telomerase Expression from Each Group
No
1
2
3
Mean
SD

Control Group
(Vero)
5
5
3
4.33
1.15

HeLa Group

WiDr Group

77
78
90
81.67
7.23

74
64
64
67.33
5.77

Raji Group
67
67
67
67.00
0.00

T47D Group

MCF7 Group

86
90
90
88.67
2.31

74
74
73
73.67
0.58

Table 2. Anova Results of the Expression of Telomerase in between Groups
Sum of square
13781.778
185.333
13967.111

Between groups
Within groups
Total

Df
5
12
17

Mean of square
2756.356
15.444

F
178.469

Sig
0.000

Table 3. Test of Multiple Comparisons (LSD) Percentage of Positive Telomerase Expression between Each Group
Group

Control group
(Vero)

Control
(Vero)
HeLa
WiDr
Raji
T47D
MCF7

HeLa

WiDr

Raji

T47D

MCF7

**

**

**

**

**

**

*
-

**
**

*
**
*
-

*significant different at p < 0.05
**there are very significant difference at p < 0.01
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key in cell immortality and tumorogenesis. Telomerase
is activated in 80-90% of human cancer cells and it is
not found in normal somatic cells so it can be used as a
marker in the diagnosis of cancer. Clinical trials for
telomerase can be useful as a non-invasive method for
the early detection and monitoring of cancer.13,14
Most normal cells or somatic cells such as fibroblasts
(Vero cells) have a limited ability to replicate is generally
40 to 50 generations, then will stop dividing, because
the normal cell undergo aging and apoptosis. This is
determined by the presence of erosions or telomere
shortening, since most normal human cells lacking
telomerase activity in the presence of strict repression of
transcription of human telomerase reverse transcriptase
(hTERT). In normal somatic cells telomere shortening,
including stem cells, which are intended for cell renewal.
So a somatic cell has the aging program.5,7,12,15 The
above results indicate that, despite the expression of
telomerase in cancer cells is much higher than the normal
cells, but in each of the cancer cells are not the same
expression. Telomerase expression is different in each
species and each type of cell will show different telomerase
expression, as did the level of develop-ment.12,16,17
Breast cancer cells showed the highest expression than
other cancer cells. Previous research on breast cancer
reported that telomerase activity is regulated by human
telomerase reverse transcriptase gene (hTERT), which
plays an important role in the growth and development
of breast cancer cells (MCF-7 and MDA-MB-231) through
the maintenance of telomere length.8 Whereas telomerase
expression in normal cells have been found in the germ
cells in the ovaries and testes, and stem cells. Whereas
in adult somatic cells telomerase expression is very low
or does not show any expression of telomerase.18 The
enzyme telomerase plays a role in every cell replication
that is able to maintain telomere length to cell
derivatives, so that if cancer cells do not have sufficient
telomerase enzyme, then the growth of cancer cells by
itself is discontinued when the enzyme is no longer able
to sustain long continuous telomere due to abnormal
proliferation control. The absence of the enzyme
telomerase can inhibit the growth of cancer cell division
by transmitting so that shorter telomeres and die before
making any further damage. However, if the cancer
cells are able to synthesise telomerase that cancer cells
will continue to proliferate and become immortal.12,19
From the description and the results above showed that
telomerase is active or high prevalence in cancer cells,
so that telomerase can be an attractive therapeutic target.
In recent years, many standard therapeutic agents used
to treat cancer that acts as an anti-telomerase. Such as in
breast cancer has been to development tamoxifen, troglitazone as anticancer agents that are anti-telomerase.6,20
On the other hand is known, that cyclooksigenase
enzyme-2 (COX-2) may play a role as well as a specific
Makara J. Health Res.
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marker that could help determine the diagnosis of
cancer. Over-expression of COX-2 plays an important
role in the carcinogenesis process. It has been reported
that the expression of COX-2 increased in some cancer
cells, such as lung cancer and breast cancer. COX-2
enzyme may increase cancer cell proliferation and
resistance to apoptosis and suppression of COX-2 will
cause apoptosis.21 Suppression of hTERT expression in
cancer cells will also improve the process of telomere
shortening, thus triggering cell senescence and
apoptosis. The target telomerase or hTERT as a strategy
in anticancer therapy, is relatively new. Inhibition of
telomerase or hTERT alone has minimal clinical
efficacy. Has conducted research for the targeting of
treatment through a combination of telomerase or
hTERT and COX-2 to work synergistically in killing
cancer cells.7 In addition to the target in therapy,
telomerase is also used as an attractive target for the
diagnosis and prognosis of breast cancer. The results of
the examination of telomerase may be a marker of breast
cancer diagnostics and improve diagnostic accuracy.
Estimates of telomerase activity in various variants of
breast cancer may predict the clinical course of the
disease and provide prognostic instructions for different
variants of breast cancer.22

Conclusions
Cancer cells have telomerase expression of specific and
different from each other, depending on the type of cell.
T47D breast cancer cells have telomerase expression of
the highest, followed by cervical cancer cells (HeLa). Lung
cancer cells (WiDr) with cell lymphoma (Raji) has almost
the same expression and both have lower expression.
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